# Perrigo Company plc (PRGO) Stock Analysis: Exploring a Potential 74.9% Upside for Savvy Investors

- Link: https://www.directorstalkinterviews.com/perrigo-company-plc-prgo-stock-analysis-exploring-a-potential-74-9-upside-for-savvy-investors/4121244948
- Published: 2026-03-17T11:23:16+00:00
- Author: Madison Wilson

Perrigo Company plc (NYSE: PRGO) presents an intriguing opportunity for investors
seeking to capitalize on potential upside in the healthcare sector. Known for its
robust portfolio of over-the-counter health and wellness solutions, Perrigo operates
across the United States, Europe, and internationally, with a diverse range of products
that cater to consumer self-care needs. With its headquarters in Dublin, Ireland,
Perrigo has established itself as a key player in the drug manufacturers’ specialty
and generic industry.

Currently trading at $9.72, Perrigo’s stock has experienced a significant decline
from its 52-week high of $28.49. This drop places the stock near the lower end of
its 52-week range, which has caught the attention of value-oriented investors. The
company boasts a market cap of $1.34 billion, positioning it as a mid-sized player
within the healthcare sector.

Despite recent revenue growth challenges, with a reported decline of 2.50%, and 
an EPS of -$10.12, the company remains a compelling proposition due to its strong
dividend yield of 11.93%. However, the extraordinarily high payout ratio of 10,950.00%
raises questions about the [sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news)
of such dividends, particularly in light of the company’s negative return on equity
of -38.66%.

Perrigo’s forward P/E ratio of 4.01 suggests that the stock may be undervalued relative
to its future earnings potential. This is further supported by analyst sentiment,
with two buy ratings and three hold ratings, and no sell ratings. The average target
price of $17.00 implies a substantial 74.90% upside from the current price, providing
a tantalizing prospect for investors willing to bet on a turnaround.

The technical indicators present a mixed picture. The stock’s RSI of 31.65 indicates
that it is approaching oversold territory, which may suggest a potential rebound
in the near term. However, both the 50-day and 200-day moving averages, at $13.57
and $19.41 respectively, show that the stock is currently trading below these levels,
reflecting a bearish trend. The MACD and signal line, at -1.28 and -1.05 respectively,
reinforce this cautious outlook, suggesting ongoing downward momentum.

Perrigo’s extensive product range, including well-known brands such as Nasonex, 
Plackers, and Mederma, provides a solid foundation for future growth. The company
continues to tap into consumer health trends, marketing its products through a variety
of retail channels, including supermarkets, e-commerce platforms, and pharmacies.
This diversified distribution strategy, combined with its focus on self-care and
wellness, positions Perrigo to leverage increasing consumer demand for health-related
products.

For investors, the critical factors to watch will include Perrigo’s ability to stabilize
revenue growth, improve its operational efficiency, and manage its dividend payouts
sustainably. Any positive developments in these areas could bolster investor confidence
and catalyze a stock price recovery.

Overall, Perrigo Company plc offers a potentially rewarding investment opportunity
for those willing to navigate the risks associated with its current financial metrics.
With its strategic market positioning and substantial upside potential, Perrigo 
may well be a stock to watch for growth-oriented investors seeking exposure to the
healthcare sector.

Share on: